Eton Pharmaceuticals (NASDAQ:ETON) PT Raised to $15.00

Eton Pharmaceuticals (NASDAQ:ETON) had its price target hoisted by investment analysts at Craig Hallum from $10.00 to $15.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Craig Hallum’s price target points to a potential upside of 77.51% from the company’s previous close.

Separately, HC Wainwright raised their target price on shares of Eton Pharmaceuticals from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Friday, October 4th.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock traded up $0.34 during midday trading on Monday, reaching $8.45. The stock had a trading volume of 157,696 shares, compared to its average volume of 83,783. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $8.64. The firm’s fifty day simple moving average is $6.02 and its 200-day simple moving average is $4.39. The stock has a market capitalization of $218.35 million, a P/E ratio of -32.50 and a beta of 1.31.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). Eton Pharmaceuticals had a negative net margin of 21.31% and a negative return on equity of 43.62%. The business had revenue of $9.07 million during the quarter, compared to the consensus estimate of $10.00 million. On average, sell-side analysts anticipate that Eton Pharmaceuticals will post -0.17 earnings per share for the current fiscal year.

Insider Buying and Selling at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. bought 57,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were acquired at an average cost of $4.65 per share, with a total value of $267,375.00. Following the acquisition, the insider now owns 2,660,000 shares of the company’s stock, valued at $12,369,000. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired 85,600 shares of company stock worth $462,674 over the last 90 days. Company insiders own 14.89% of the company’s stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ETON. Westside Investment Management Inc. lifted its stake in shares of Eton Pharmaceuticals by 1.9% during the 1st quarter. Westside Investment Management Inc. now owns 573,960 shares of the company’s stock worth $2,152,000 after buying an additional 10,850 shares during the last quarter. Acadian Asset Management LLC lifted its position in Eton Pharmaceuticals by 13.7% during the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after acquiring an additional 18,898 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after acquiring an additional 41,469 shares during the period. Stonepine Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals in the second quarter valued at approximately $362,000. Finally, Thompson Siegel & Walmsley LLC bought a new position in shares of Eton Pharmaceuticals during the second quarter worth approximately $420,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.